Opioids are very effective analgesics, but they are also highly addictive. Methadone is used to treat opioid dependence (OD), acting as a selective agonist at the μ-opioid receptor encoded by the gene OPRM1. Determining the optimal methadone maintenance dose is time consuming; currently, no biomarkers are available to guide treatment. In methadone-treated OD subjects drawn from a case and control sample, we conducted a genome-wide association study of usual daily methadone dose. In African-American (AA) OD subjects (n = 383), we identified a genome-wide significant association between therapeutic methadone dose (mean = 68.0 mg, s.d. = 30.1 mg) and rs73568641 (P = 2.8 × 10 − 8 ), the nearest gene (306 kilobases) being OPRM1. Each minor (C) allele corresponded to an additional~20 mg day − 1 of oral methadone, an effect specific to AAs. In European-Americans (EAs) (n = 1027), no genomewide significant associations with methadone dose (mean = 77.8 mg, s.d. = 33.9 mg) were observed. In an independent set of opioid-naive AA children being treated for surgical pain, rs73568641-C was associated with a higher required dose of morphine (n = 241, P = 3.9 × 10 − 2 ). Similarly, independent genomic loci previously shown to associate with higher opioid analgesic dose were associated with higher methadone dose in the OD sample (AA and EA: n = 1410, genetic score P = 1.3 × 10 − 3 ). The present results in AAs indicate that genetic variants influencing opioid sensitivity across different clinical settings could contribute to precision pharmacotherapy for pain and addiction.
INTRODUCTION
Opioids are efficacious analgesics that also have considerable addictive properties. In recent years, the United States has faced an opioid abuse epidemic. 1 The rate of fatal overdoses from prescription opioids has quadrupled. 2 National prescribing guidelines recently announced by the Centers for Disease Control and Prevention are intended to curb the excessive clinical use of opioids and to promote evidence-based therapies for patients who develop opioid dependence (OD). 3 For decades, the mainstay of evidence-based OD treatment has been the pairing of supportive social services with opioid substitution therapy. 4, 5 Methadone is an inexpensive and longacting synthetic opioid, and similar to the most frequently abused opioids, it is a potent μ-opioid receptor agonist. 6 Methadone maintenance therapy (MMT) can therefore be used to treat abuse by pharmacologically substituting for other opioids, such as morphine or heroin. MMT reduces craving, withdrawal symptoms and risk of relapse. 6 The initial, or induction, stage of MMT requires considerable care: excessive methadone doses are dangerous, 7 while overly conservative dosing is ineffective at preventing relapse to illicit opioid use. 8 Determining the clinically optimal dose, one that provides clinical benefit to a particular individual without causing sedation or respiratory depression, is time consuming. Methadone dosing must be adjusted based on clinical signs and symptoms, and patients differ greatly in their dose requirements. Despite the clinical challenges posed by methadone administration and resistance to MMT for social and cultural reasons, 9, 10 MMT remains a vitally important treatment strategy for hundreds of thousands of patients in the United States. 11 Opioids such as methadone and morphine are full agonists at the μ-opioid receptor, which is encoded by the gene OPRM1 on chromosome 6. 6 OPRM1 has been the subject of intense interest, particularly the common missense single-nucleotide polymorphism (SNP) rs1799971, but also non-coding variation, with dozens of candidate gene association studies having examined a wide range of phenotypes. [12] [13] [14] Many of the initial claims about associations between the candidate missense variant rs1799971 and clinical phenotypes have not proven to be robust, 15, 16 although modest effects do appear to be present. 17, 18 In addition to OPRM1, studies have also examined the relationship between methadone metabolism and candidate polymorphisms in genes encoding cytochrome P450 enzymes, including CYP3A4, CYP2B6 and CYP2D6. [19] [20] [21] Neither metabolic enzyme polymorphisms nor serum methadone levels have yet been shown to be reliable 1 predictors of maintenance dose. 22, 23 Genes related to both pharmacodynamics and pharmacokinetics may, however, influence each individual's dosing needs.
Genome-wide association studies (GWASs) survey the entire catalog of common genetic variants in a hypothesis-free manner. OPRM1 is an obvious gene of interest, but prior studies of complex traits have repeatedly demonstrated that unbiased approaches are important for discovering phenotypically relevant SNPs. [24] [25] [26] We performed a GWAS to search for pharmacogenetic determinants of daily methadone dose in a sample of methadone-treated OD subjects, and followed up our findings using morphine dose data from an independent clinical sample being treated for acute pain. In this way, we sought to identify and characterize SNPs that associate with therapeutic opioid dose, which could enable personalized treatment of individuals based on their genotype.
MATERIALS AND METHODS
Recruitment and assessment of subjects with OD Details on the Yale-Penn sample have been published previously. 24, 27, 28 Briefly, adults with a history of dependence on alcohol, opioids or cocaine and controls were recruited at five sites in the eastern United States, primarily via community advertisements and word of mouth, as part of ongoing studies of drug and alcohol dependence genetics. The sample consisted of small nuclear families with affected and unaffected members (originally collected for linkage studies), and unrelated cases and controls. Exclusion criteria included a history of psychotic disorders (schizophrenia, bipolar disorder), serious head injury or inability to read English at a sixth-grade level. Subjects gave written informed consent as approved by the institutional review board (IRB) at each site, and certificates of confidentiality were obtained from the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism. In-person interviews were conducted by trained interviewers using the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA), which is a comprehensive polydiagnostic instrument that yields reliable information on major Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnoses and diagnostic criteria (available at https://nidagenetics.org/filebrowser/ download/3765). 29, 30 The SSADDA covers psychiatric and substance use disorders, as well as social and medical history and demographic information.
Methadone dose GWAS in methadone-treated OD subjects DNA from study participants was extracted from blood, saliva or immortalized cell lines. Subjects were genotyped using either the Illumina HumanOmni1-Quad_v1.0 microarray (Illumina, San Diego, CA, USA) or the Illumina Human Core Exome microarray (Illumina). Subjects were genotyped on the HumanOmni1-Quad_v1.0 at the Yale Center for Genome Analysis or the Center for Inherited Disease Research. The HumanOmni1-Quad_v1.0 contains 988 306 autosomal SNPs, and genotypes were called using the Illumina Genome Studio software v2011.1, genotyping module v1.8.4. Subjects were initially filtered based on call rate, and SNPs filtered based on call rate and frequency, with identity-by-descent estimates used to quantify genetic relatedness between subjects. Extensive details on genotyping and data cleaning procedures have been published previously. 24 Subjects genotyped on the HumanOmni1-Quad_v1.0 were included in the present study if they were unrelated and either self-reported African-Americans (AAs) or European-Americans (EAs), with population outliers then removed based on principal component analysis of genotype data. 31, 32 Subjects not genotyped on the HumanOmni1-Quad_v1.0 were genotyped on the Human Core Exome microarray, which contains both exome-focused SNP content and tagging SNPs for genome-wide imputation. Details about the application of quality control procedures to the Human Core Exome microarray data are provided in Supplementary Methods. Genotype data are being released via the National Institutes of Health (NIH) dbGAP platform (accession number phs000425.v1.p1).
All subjects selected for the GWAS met criteria for DSM-IV OD. Subjects who had been treated with methadone were asked the following question: 'When you were taking methadone, what was your usual dosage?' Data on daily methadone dose were available for a total of 383 AAs and 1027 EAs. Phenotype data were prepared for GWAS using the R statistical computing environment, 33 which was also used to generate phenotype data summary statistics (means, s.d.). Methadone dose data, in milligrams (mg), were transformed to normality with an inversenormal transformation 34 and used as the dependent variable in the GWAS. As previously described, imputation of genotype data was performed from the 1000 Genomes Project Phase 1 reference panel using Impute2. [35] [36] [37] The GWAS was carried out with Plink v1. 07, 38 adjusting for age, sex, weight and 10 principal components. Within each of the two ancestry groups (EA and AA), separate analyses were run on subjects genotyped on the HumanOmni1-Quadv1.0 and Human Core Exome microarrays. SNPs were filtered out if the minor allele frequency (MAF) was o 5% or if the imputation INFO score was o 0.7. Meta-analyses were then performed within ancestry groups using METAL, which was also used to remove SNPs with heterogeneous effect estimates across the two microarrays, and to adjust summary statistics based on the genomic inflation factor (λ). 39 LocusZoom was used for regional association plot generation. 40 We defined the cutoff for genome-wide significance using the criterion of P = 5.0 × 10 − 8 .
Intravenous morphine dose data from opioid-naive pediatric surgery patients Children aged 4-18 years who received intravenous morphine during a tonsillectomy and adenoidectomy at the Children's Hospital of Philadelphia (CHOP) were identified using the Anesthesia Information Management system (CompuRecord, Phillips Medical Systems, Andover, MA, USA). All surgeries were performed between 1 November 2001 and 1 December 2009. Exclusion criteria included obstructive sleep apnea, a combination of tonsillectomy and adenoidectomy with another procedure or administration of other intraoperative anesthetics. While recovering in the Postanesthesia Care Unit, children received additional intravenous morphine (in 25-50 μg kg − 1 increments) to control their pain. The CHOP IRB approved collection of these data.
A subset of the patients meeting the above inclusion criteria had previously been consented for genomic study and genotyped (on either the Illumina Human-Hap550 or Illumina Human610-Quad microarray) by the Center for Applied Genomics at CHOP, as approved by the CHOP IRB. Sample details and quality control of phenotype and genotype data have been described previously. 41 The 1000 Genomes Project reference panel and Impute2 [35] [36] [37] were used to impute the top methadone dose GWAS SNP. In this morphine-treated sample, we analyzed total intravenous morphine dose (μg kg − 1 ) as a quantitative trait and used SNPTEST V2 42 to evaluate the methadone dose GWAS-identified SNP. We used the same statistical model previously developed for this sample, which included age, body mass index and American Society of Anesthesiologists physical status as covariates. 41 
RESULTS
Methadone dose GWAS in the Yale-Penn OD sample identifies a significant association upstream of OPRM1 at rs73568641 Table 1 provides an overview of the GWAS sample demographics. Supplementary Table S1 , and summary statistics for all SNPs with P o 5.0 × 10 − 5 in EAs are provided in Supplementary Table S2 . The GWAS conducted in AAs identified one genome-wide significant region on chromosome 6 (lead SNP rs73568641, n = 383, P = 2.8 × 10 − 8 , Supplementary  Table S3 ; AA quantile-quantile (QQ) plot is shown in Supplementary Figure S3 ). Lead SNP rs73568641 tags an association peak approximately~300 kilobases (kb) upstream of the OPRM1 transcription start site (Figure 1 ). Rs73568641 genotypes did not deviate from Hardy-Weinberg equilibrium expectations. 43 In AAs, the minor (C) allele of rs73568641 (MAF = 0.1) was associated with a higher daily methadone dose: TT genotype (n = 310), dose mean (s. Figure 2 displays the usual daily methadone dose for each AA subject, stratified by rs73568641 genotype. The association between methadone dose and rs73568641 was specific to AAs (EA n = 1027, MAF = 0.17, P = 0.32, Supplementary Table S3) , and no SNPs were genome-wide significant in the GWAS conducted in the EA sample (EA QQ plot is shown in Supplementary Figure S4) . Manhattan plots are shown in Supplementary Figure S5 . In an exploratory analysis across samples evaluating previously studied candidate alleles from genes encoding methadonemetabolizing enzymes, 44 we found suggestive evidence that the CYP2D6 loss-of-function variant rs3892097 is associated with lower methadone dose (AA and EA n = 1410, P = 2.6 × 10 − 3 ; Supplementary Table S4) . A genome-wide meta-analysis of the AA and EA samples did not reveal additional genome-wide significant variants.
Methadone dose-associated SNP rs73568641 also associates with morphine dose in the CHOP pediatric surgical patients We investigated whether the implicated SNP upstream of OPRM1 also influences sensitivity to the analgesic effects of opioids. Because the observed association between rs73568641 and methadone dose was evident only in AAs, we examined the effect of rs73568641 in an independent AA sample. The only published GWAS of opioid dosage in AAs that we are aware of is our earlier study, 41 wherein we examined intravenous morphine dose in AA pediatric patients recovering from tonsillectomy and adenoidectomy. In these AA subjects (dose mean (s.d.) = 118.6 μg kg )), rs73568641-C was associated with a higher required morphine dose (n = 241, β = 11.6 μg kg )), no association between rs73568641-C and morphine dose was present (n = 277, P = 0.33). These consistent results across independent samples indicate that the effects of the locus are apparent in African-ancestry but not in European-ancestry populations (no other populations were tested). Figure 1 . Genome-wide significant association with methadone dose in opioid-dependent African-Americans (AAs). Regional association plot of the implicated locus on chromosome 6, showing a genome-wide significant association between methadone dose and single-nucleotide polymorphism (SNP) rs73568641 (purple) (AA n = 383, P = 2.8 × 10
). The gene nearest to rs73568641 is OPRM1. Each circle corresponds to a SNP, and the vertical position reflects the − log 10 (P value) (left y axis). Color coding depicts the degree of linkage disequilibrium (r 2 ) between lead SNP rs73568641 and other SNPs in the region. The blue line indicates the recombination rate (right y axis). Centimorgan (cM), megabase (Mb). Opioid analgesic dose GS associates with higher methadone dose in the Yale-Penn OD sample Prior GWASs have identified several top SNPs that, while not reaching genome-wide significance, associated replicably with higher opioid analgesic dose, and implicated genes CREB1, TAOK3 and TRPC3. 41, 45, 46 We found that a genetic score (GS) calculated using these dose-increasing alleles was associated with higher methadone dose and that the relationship was more evident in AAs than in EAs (AA: n = 383, two-tailed P = 6.6 × 10 − 4 ; EA: n = 1027, two-tailed P = 8.0 × 10 − 2 ; meta-analysis P = 1.3 × 10 − 3 , Supplementary Table S5) (an explanation of how the GS was derived is provided in Supplementary Methods).
DISCUSSION
In methadone-treated AA OD subjects, a GWAS identified a genome-wide significant association with methadone dose, with the nearest gene being OPRM1. This same SNP was associated with increased morphine dose in an independent sample of AA surgical patients. We also found evidence that previously identified opioid analgesic dose-associated SNPs (mapping to three different genomic locations, all separate from OPRM1) associated with higher methadone dose in the total sample of methadone-treated OD subjects. These results therefore indicate that the top genetic predictors of opioid dose in the setting of addiction treatment also influence the opioid dose needed to achieve analgesia and vice versa.
Despite the current OD epidemic, effective pharmacotherapies are grossly underutilized. 47 Buprenorphine has emerged as an office-based treatment for OD, but in a Cochrane review methadone was more effective than buprenorphine when delivered at an adequate dosage. 48 Overly conservative dosing undermines clinical effectiveness, [49] [50] [51] although clinicians must also be careful to minimize the danger of doses that are too high for their patients. 52 The initiation of methadone treatment is therefore particularly challenging. The dosage required varies widely, and there are no methods available at the start of treatment to predict the optimal dose for a particular patient. 22 Similar patient-to-patient variability is also seen when opioids are used for pain control, and a substantial portion of this variance has been attributed to heritable factors. 53 The association signal that we identified is far enough upstream from the OPRM1 coding region-about 300 kb for the lead SNPto have entirely escaped interrogation in the many previous OPRM1 candidate gene studies. 12 The identified locus is noncoding, as is often seen in GWASs, and its molecular function remains unknown. Mechanistic studies in genetically engineered neural cultures might shed light on how the μ-opioid receptor's response to exogenous opioids differs by genotype. 54 We cannot rule out the possibility that, although OPRM1 is the closest gene, the association is partially, or even entirely, attributable to cis or trans effects on the expression or function of proteins encoded elsewhere in the genome.
Genetic variants at loci related to methadone metabolism may also be clinically relevant, but their study has been complicated by the presence of differently metabolized optical isomers, 55 the use of different experimental paradigms 20, 21, [56] [57] [58] and the possible tissue specificity of enzymatic activity. 59, 60 Our suggestive finding that a CYP2D6 loss-of-function allele 61, 62 decreases required methadone dose is in the expected direction. Future applications of genetics to dosage prediction could incorporate genetic variation at known pharmacokinetic and pharmacodynamic genes, as well as additional genes such as those implicated by the GS. These additional genes point to relevant biology beyond the interface of opioids with metabolizing enzymes or the μ-opioid receptor, illustrating the importance of unbiased GWASs that are not driven by prior hypotheses.
In the present samples, the association between rs73568641-C and higher opioid dose was observed only in AAs for both methadone and morphine. In our prior OD GWAS, 24 which included most of the Yale-Penn subjects in the present study, we similarly reported very different results for AAs and EAs, with the most significant results (which did not include any markers near OPRM1) in AAs. In the present study, the GS association signal was stronger in methadone-treated AAs than EAs. There are several possible explanations that could account for associations being preferentially detected in specific populations. GWAS SNPs often tag many common variants, as is the case here (Figure 1 ), and population-specific GWAS findings 63 may be related to linkage disequilibrium between common SNPs and populationspecific rare functional variants. 64 Whole-genome sequencing approaches and larger samples will be needed to interrogate fully variation across the allele frequency spectrum in multiple ancestry groups. Epistasis provides another possible explanation; some polymorphisms may have phenotypic effects only when population-specific variants in the region or even elsewhere in the genome are present to interact with them. 65 Clinicians tend to prescribe lower doses of opioids to minority patients for pain control, 66 including minority children. 67 Although clinical confounds may partly explain this phenomenon, a similar pattern is observed in the setting of substance use disorders: OD treatment programs serving a higher proportion of AA patients are more likely to report under-dosing of methadone. 51 We observed lower opioid doses for AAs compared with EAs (methadone: t-test P o0.001; morphine: t-test P o0.001). The present data are therefore consistent with the hypothesis that prescriber bias may contribute to differences between population groups in the quantity of opioids dispensed, although we cannot exclude the possibility that the observed differences in dosing may reflect actual differences in medication requirements. 68 If EA subjects are dosed more liberally than AA subjects, who receive doses closer to the therapeutic minimum or are undertreated, objective markers to guide dosing could serve to mitigate underdosing and consequent health disparities.
A limitation of our study is the sample size, which is small compared with case/control mega-GWASs that pool data across many different studies each having only limited phenotype information. In particular, future recruitment of additional methadone-and morphine-treated patients will be needed in order to study large numbers of CC homozygotes. Generally, pharmacogenomics GWASs tend to have many fewer subjects than studies of disease risk, because it is challenging to recruit and clinically characterize informative subjects, although the observed effect sizes are often greater in pharmacogenomics studies. 69 Our GWAS is larger than all previously published opioid dose GWASs of which we are aware, 41, 45, 46, 70 and our GS finding reinforces that these earlier GWASs were likely successful in identifying real signals despite modest sample sizes. Thus the larger present sample would seem to be sufficient, especially considering the validation of rs73568641 in an independent sample of morphinetreated patients. Evaluation of rs73568641 using clinically documented morphine dose data also helps to compensate for another limitation of our study, which is that the data on usual daily methadone dose was collected via self-report. The intensive daily nature of methadone treatment, which allows for close monitoring of clinical response and provides frequent reminders to the patient of their dose, further supports the reliability of the reported methadone dose data. One study found that, when OD subjects receiving methadone were interviewed in a research setting, the correlation coefficient between self-reported and clinically documented dosage was 0.97. 71 In the field of pharmacogenomics, strong positive results have been produced by studying medications that require clinicians to tailor carefully the dose to each individual patient's needs. 69 An initial GWAS of warfarin dose in 181 patients detected a genomewide significant association signal upstream of the gene (VKORC1) encoding the drug's target. 72 The case of warfarin is instructive for the study of methadone, providing an example of efforts to clinically implement genotype-guided dosing. 73 Warfarin differs from methadone, however, in that the International Normalized Ratio test can provide precise biochemical feedback to guide warfarin dosing, making it difficult for genotype-based algorithms to improve on treatment as usual. 74, 75 In contrast, there are currently no biological assays to help clinicians decide which patients will require more aggressive methadone dosing, suggesting that genetics could have a role in improving clinical outcomes. Prospective studies, including randomized controlled trials of genotype-guided dosing, are needed to define better the magnitude of the genetic contribution to dose requirements and to assess the clinical utility of this information.
CONCLUSIONS
In methadone-treated OD AAs, we identified a single genomewide significant association with methadone dosing needs and found that the closest gene was OPRM1. We validated the genetic marker in an independent sample of AA surgical patients receiving morphine for analgesia. Consistent with the observation that this SNP's influence is evident across different clinical settings where μ-opioid receptor agonism is employed, top SNPs from prior opioid analgesic dose studies were collectively associated with methadone dose in OD patients. The observed effect of the rs73568641 minor allele on methadone dose requirements could have immediate clinical utility in the therapeutic dosing of methadone, and perhaps other μ-opioid receptor agonists, in AA patients. Prospective replication and further clinical characterization in new samples are needed to realize this potential.
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